Diabetic Nephropathy Market Booming: Predicted to Reach USD 3.97 Billion by 2032

The global Diabetic Nephropathy Market was valued at USD 2.71 billion in 2024 and is projected to reach USD 3.97 billion by 2032, with a CAGR of 4.98%. The U.S. market alone was valued at USD 0.79 billion in 2024 and is expected to hit USD 1.13 billion by 2032 due to factors like early adoption of SGLT2 inhibitors and increasing type-2 diabetes cases.

Diabetic nephropathy is a serious complication of diabetes and a leading cause of end-stage renal disease globally. Technological and pharmacological advancements, especially SGLT2 inhibitors, are transforming disease management. The U.S. has high rates of diabetes, robust healthcare systems, and proactive government policies supporting the early adoption of novel therapies.

Major players in the market include AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, and more. The market size in 2024 was USD 2.71 billion and is expected to reach USD 3.97 billion by 2032, with a CAGR of 4.98%. The market is segmented by type, drug class, and distribution channel, with the Type-2 Diabetes segment dominating in 2024.

North America leads the Diabetic Nephropathy Market with a 38.2% market share in 2024, due to high diabetes prevalence and established healthcare infrastructure. Asia Pacific is expected to be the fastest-growing region, driven by the increasing burden of type-2 diabetes in countries like India and China. Urbanization and changing lifestyles are contributing to market expansion in this region.

Read more at GlobeNewswire: Diabetic Nephropathy Market Set to Reach USD 3.97 Billion